Status:

COMPLETED

Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)

Lead Sponsor:

Mansoura University

Conditions:

Acute Heart Failure

Eligibility:

All Genders

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), increases natriuresis alone and synergistically when combined with loop diuretics in patients with AHF without increasing renin angi...

Eligibility Criteria

Inclusion

  • Adults aged 18 years or older who are hospitalized for hypervolemic AHF, with evidence of congestion defined as either:
  • \* 2 of the following signs or symptoms: peripheral edema, ascites, jugular venous pressure \> 10mmHg, orthopnea, paroxysmal nocturnal dyspnea, 5-pound weight gain, or signs of congestion on chest x-ray or lung ultrasound.
  • OR
  • \*If pulmonary artery catheterization is available, a pulmonary capillary wedge pressure greater than 19 mmHg plus a systemic physical exam finding of hypervolemia from the list above.
  • Randomized within 24 hours of hospitalization for AHF
  • Planned use of IV loop diuretic therapy during current hospitalization
  • Estimated glomerular filtration rate (eGFR) of at least 30 ml/min/1.73m2 by the MDRD equation
  • For diabetic patients, history of type 2 diabetes or a new hemoglobin A1c 6.5% on admission.

Exclusion

  • Type 1 diabetes mellitus.
  • Dyspnea primarily due to non-cardiac causes.
  • Cardiogenic shock.
  • Acute coronary syndrome within 30 days prior to randomization.
  • Planned or recent percutaneous or surgical coronary intervention within 30 days prior to randomization.
  • Signs of ketoacidosis and/or hyperosmolar hyperglycemic syndrome (pH\>7.30 and glucose \>15 mmol/L and HCO3\>18 mmol/L).
  • Pregnant or nursing (lactating) women.
  • Heart failure due to drug toxicity
  • Adherence to medication less than 95%

Key Trial Info

Start Date :

April 25 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2023

Estimated Enrollment :

87 Patients enrolled

Trial Details

Trial ID

NCT05406505

Start Date

April 25 2022

End Date

July 1 2023

Last Update

August 4 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Noha Mansour

Al Mansurah, Egypt, 35516